Cochlear Ltd
Company Profile
Business description
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2026, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 16% from the Asia-Pacific segment.
Contact
1 University Avenue
Macquarie University
SydneyNSW2109
AUST: +61 294286555
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
Employees
4,749
Cochlear Ltd News & Analysis
stocks
Reporting season was stronger than share prices suggest
markets
The grass is always greener: Rethinking Australian vs global equities
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,198.30 | 37.90 | 0.41% |
| CAC 40 | 8,258.04 | 22.59 | -0.27% |
| DAX 40 | 25,816.72 | 22.61 | -0.09% |
| Dow JONES (US) | 53,061.95 | 295.07 | 0.56% |
| FTSE 100 | 10,775.98 | 19.53 | 0.18% |
| HKSE | 25,213.31 | 97.90 | -0.39% |
| NASDAQ | 26,217.83 | 118.05 | 0.45% |
| Nikkei 225 | 64,214.48 | 111.16 | -0.17% |
| NZX 50 Index | 13,846.18 | 84.39 | -0.61% |
| S&P 500 | 7,666.60 | 35.13 | 0.46% |
| S&P/ASX 200 | 9,020.10 | 46.10 | 0.51% |
| SSE Composite Index | 3,942.09 | 0.70 | 0.02% |